bluebird bio, Inc. (NASDAQ:BLUE) had its price objective lifted by SunTrust Banks, Inc. from $108.00 to $163.00 in a report published on Friday morning. SunTrust Banks, Inc. currently has a buy rating on the biotechnology company’s stock.
BLUE has been the topic of several other research reports. Jefferies Group LLC restated a buy rating and issued a $88.00 target price on shares of bluebird bio in a report on Friday, August 11th. Zacks Investment Research cut shares of bluebird bio from a buy rating to a hold rating in a report on Tuesday, July 18th. BidaskClub cut shares of bluebird bio from a hold rating to a sell rating in a report on Wednesday, August 2nd. Morgan Stanley raised bluebird bio from an underweight rating to an equal weight rating in a research note on Friday. Finally, Evercore ISI raised bluebird bio from an in-line rating to an outperform rating and set a $102.00 price target for the company in a research note on Monday, October 16th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the company’s stock. bluebird bio currently has an average rating of Buy and an average target price of $131.05.
Shares of bluebird bio (NASDAQ BLUE) traded down $10.07 during midday trading on Friday, reaching $146.18. 585,799 shares of the company’s stock were exchanged, compared to its average volume of 855,072. bluebird bio has a twelve month low of $41.25 and a twelve month high of $164.80.
bluebird bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The firm had revenue of $7.71 million during the quarter, compared to the consensus estimate of $8.47 million. During the same quarter in the prior year, the business posted ($2.07) EPS. The firm’s revenue for the quarter was up 397.4% on a year-over-year basis. equities research analysts predict that bluebird bio will post -6.76 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “bluebird bio, Inc. (BLUE) Price Target Raised to $163.00” was posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.com-unik.info/2017/11/06/bluebird-bio-inc-blue-price-target-raised-to-163-00.html.
In related news, insider Jeffrey T. Walsh sold 1,250 shares of bluebird bio stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $95.41, for a total value of $119,262.50. Following the completion of the sale, the insider now directly owns 28,555 shares in the company, valued at approximately $2,724,432.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Nick Leschly sold 46,833 shares of bluebird bio stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $122.27, for a total value of $5,726,270.91. Following the completion of the sale, the insider now owns 289,368 shares of the company’s stock, valued at $35,381,025.36. The disclosure for this sale can be found here. Insiders sold a total of 185,518 shares of company stock valued at $24,292,373 over the last quarter. 3.90% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the business. QS Investors LLC grew its stake in shares of bluebird bio by 70.7% during the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 500 shares during the period. Bank of Montreal Can grew its stake in shares of bluebird bio by 118.9% during the 2nd quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 911 shares during the period. Turner Investments LLC bought a new stake in shares of bluebird bio during the 2nd quarter valued at about $184,000. SG Americas Securities LLC grew its stake in shares of bluebird bio by 17.9% during the 2nd quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 295 shares during the period. Finally, Fairfield Bush & CO. bought a new stake in shares of bluebird bio during the 2nd quarter valued at about $210,000.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
What are top analysts saying about bluebird bio Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for bluebird bio Inc. and related companies.